Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
Date:10/27/2008

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.

The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF).

The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall Institute (WEHI) that antagonism of G-CSF or its receptor could ameliorate inflammatory conditions such as rheumatoid arthritis.

Under the terms of the restructure, CSL will now take full control of the program, including development and commercialisation of any potential drugs arising from the program. In return, MuriGen will receive certain payments - the details of which are undisclosed.

Dr Nick Samaras, MuriGen's Chief Executive Officer, said, "We are extremely pleased that the further development of the G-CSF inflammatory disease program will be conducted by an Australian biopharmaceutical partner with the expertise and capability that CSL provide. This partnership is another major milestone for MuriGen and is further evidence of the high quality portfolio the company has in-licensed from the Walter and Eliza Hall Institute. MuriGen will continue to focus on its other programs, including the development of a novel class of antiapoptotic compounds."

"This is an important step in the translation of the Institute's intellectual property," explains Dr Julian Clark, Head of Business Development at WEHI. Clark continues, "Starfish Ventures' investment in MuriGen enabled us to bring this project to a stage where CSL can now use their considerable resources and track record to progress development towards the c
'/>"/>

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... done and now they,ve done it. What,s more, they did ... U.S. Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... the first experimental demonstration of GRIN for gradient index ... a wide range of exotic optics, including superfast computers based ...
... 2011 Amgen (Nasdaq: AMGN ) and ... into a definitive acquisition agreement under which Amgen has ... venture-funded,  biotechnology company headquartered in Woburn, Mass. BioVex is ... Phase 3 clinical development, that may represent a new ...
... (Nasdaq: CEPH ) will hold a public memorial service ... and CEO on February 1, 2011, at 6:00 p.m. at The ... Dr. Baldino founded Cephalon in 1987 and led the ... ten biotechnology companies in the world. He was a recognized pioneer ...
Cached Biology Technology:GRIN plasmonics 2GRIN plasmonics 3GRIN plasmonics 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 2Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 3Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 4Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 5Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 6Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass 7Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
(Date:4/23/2014)... 2014) A team of researchers in ... into the brains of nonhuman primates and assessed ... months found that the hNSCs had differentiated into ... tumors. , The study will be published in ... but is currently freely available on-line as an ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... One of the challenges of gene therapy - a ... (DNA or RNA) - is to assure that this material ... a substantial amount along the way and without producing any ... the use of different types of vectors, molecules capable of ...
... shellfish safer to eat has been pioneered by scientists at ... Institute for Agri-Food and Land Use, not only ensures shellfish ... but is likely to revolutionise the global fishing industry. While ... takes up to two days, the new test slashes the ...
... Aware, Inc. (Nasdaq: AWRE ), a leading ... industries, today announced that on January 5, 2011 its Board ... S. Stafford, III to the Aware Board of Directors.   ... Director and will serve on the Board,s Nominating and Corporate ...
Cached Biology News:Nanodisk gene therapy 2Shellfish safer to eat thanks to breakthrough by Queen's scientists 2Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3